Sullivan Harold C, Dean Christina L, Liwski Robert S, Biswas Shilpee, Goodman Abigail L, Krummey Scott, Gebel Howard M, Bray Robert A
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
Hum Immunol. 2018 Oct;79(10):711-715. doi: 10.1016/j.humimm.2018.08.001. Epub 2018 Aug 3.
Flow cytometric crossmatches (FCXM) are routinely performed to support living-donor renal transplantation. While long a laboratory mainstay, a physical crossmatch is costly, time consuming, and frequently poses interpretative conundrums with both false-positive and false- negative results. Given the increased utilization of the virtual crossmatch (vXM) in the deceased donor setting, our aim was to assess its utility in living donor evaluations. We reviewed 100 living donor FCXMs and retrospectively performed a vXM for each pair. Seventy-five (75) cases were concordant, (i.e., FCXM-/vXM- or FCXM+/vXM+) while 25 cases were discordant; Five were vXM+/FCXM- and 20 were FCXM+/vXM-. Since donor-specific antibodies (DSA) were not detected in the 20 FCXM+/vXM- cases, these were interpreted as false-positive, i.e., due to non-HLA antibodies. Importantly, none of these patients, when transplanted across a positive FCXM, experienced early antibody mediated rejection or subsequently developed HLA DSA. These data reveal that, for the vast majority of living donor evaluations, a vXM is an acceptable vetting procedure.
流式细胞术交叉配型(FCXM)常用于支持活体供肾移植。虽然长期以来一直是实验室的主要检测方法,但实体交叉配型成本高、耗时,且经常因假阳性和假阴性结果带来解释难题。鉴于虚拟交叉配型(vXM)在 deceased 供体环境中的使用增加,我们的目的是评估其在活体供体评估中的效用。我们回顾了 100 例活体供体 FCXM,并对每一对进行了回顾性 vXM。75 例(75 例)结果一致(即 FCXM-/vXM- 或 FCXM+/vXM+),而 25 例结果不一致;5 例为 vXM+/FCXM-,20 例为 FCXM+/vXM-。由于在 20 例 FCXM+/vXM- 病例中未检测到供体特异性抗体(DSA),这些病例被解释为假阳性,即由于非 HLA 抗体。重要的是,这些患者中没有一例在通过阳性 FCXM 进行移植时经历早期抗体介导排斥反应或随后产生 HLA DSA。这些数据表明,对于绝大多数活体供体评估,vXM 是一种可接受的审查程序。